74 results
10-K
2023 FY
EX-10.4
CPRX
Catalyst Pharmaceuticals Inc
Annual report
28 Feb 24
5:16pm
10-K
2023 FY
EX-10.1
CPRX
Catalyst Pharmaceuticals Inc
Annual report
28 Feb 24
5:16pm
10-K
2023 FY
EX-10.1
CPRX
Catalyst Pharmaceuticals Inc
Annual report
28 Feb 24
5:16pm
10-K
2023 FY
EX-10.1
CPRX
Catalyst Pharmaceuticals Inc
Annual report
28 Feb 24
5:16pm
10-K
2023 FY
EX-10.1
CPRX
Catalyst Pharmaceuticals Inc
Annual report
28 Feb 24
5:16pm
8-K
EX-10.3
itr0e6ur 4n
21 Jul 23
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:30pm
8-K
EX-10.1
0z56hgv5 3jxb
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
8-K
EX-10.2
bkcc3i gh6sqq
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
8-K
EX-10.2
zb9noimyly15bz
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-10.1
ucm9eusb4jo5s10 g09q
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-10.1
wgyfhx
9 Sep 22
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.2
u6roi32x93d4 5z
12 Jul 22
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus
8:30am
8-K
EX-10.1
jo8k xfq6
12 Jul 22
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus
8:30am
8-K
EX-10.1
c9o12c1zgdfqam9
30 Jun 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
bxeai85u a9eu63drnc
11 Sep 20
Departure of Directors or Certain Officers
5:00pm
8-K
EX-10.1
zdi 8l96ziwwt49q4
20 Aug 20
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada
5:15pm
8-K
EX-10.1
5uzqprhfdwfhjcph7fwf
13 May 20
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
him tm1wn89tuxuep4
30 May 19
Catalyst Pharmaceuticals Announces Expansion of Firdapse License
5:02pm